Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 avr. 2019 16h30 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM Mass. and CRESTWOOD, Ky., April 05, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
22 mars 2019 16h30 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM Mass., and CRESTWOOD, Ky., March 22, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 mars 2019 18h00 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass. and CRESTWOOD, Ky., March 12, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
11 mars 2019 16h01 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM Mass. and CRESTWOOD, Ky., March 11, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
07 mars 2019 07h00 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass. and CRESTWOOD, Ky., March 07, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock
06 mars 2019 16h00 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM Mass. and CRESTWOOD, Ky., March 06, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals to Present at the Cowen 39th Annual Health Care Conference
04 mars 2019 16h00 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM Mass. and CRESTWOOD, Ky., March 04, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Resumes Dosing in Its Phase 3 Program for Patients with Geographic Atrophy
04 mars 2019 07h00 HE
|
Apellis Pharmaceuticals, Inc.
No inflammation observed in ten patients dosed in Phase 1b trial with new intravitreal APL-2 drug product from modified manufacturing process CRESTWOOD, Ky. and WALTHAM, Mass., March 04, 2019 ...
Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals® for APL-2 in Hematologic Indications
28 févr. 2019 10h00 HE
|
Apellis Pharmaceuticals, Inc.
Apellis to receive up to $120 million in upfront and near-term milestone payments, with the potential for additional payments subject to mutual agreement Apellis retains exclusive worldwide...
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
26 févr. 2019 17h00 HE
|
Apellis Pharmaceuticals, Inc.
Phase 3 Geographic Atrophy Program Expected to Restart By or In Q2 2019 Phase 3 Trial of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria Expected to be Fully Enrolled by End of Q2 2019 ...